BioMarin Pharmaceutical (BMRN) Financials

$59.19 +0.02 (+0.03%)

As of 12:10 PM Eastern

Annual Income Statements for BioMarin Pharmaceutical

This table shows BioMarin Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-172	-630	-117	-77	-24	854	-64	142	168	427
Consolidated Net Income / (Loss)	-172	-630	-117	-77	-24	854	-64	142	168	427
Net Income / (Loss) Continuing Operations	-172	-630	-117	-77	-24	854	-64	142	168	427
Total Pre-Tax Income	-155	-831	-36	-143	-95	-49	-75	150	189	542
Total Operating Income	-111	-803	-15	-124	-100	-43	-82	161	186	484
Total Gross Profit	738	907	1,072	1,176	1,345	1,336	1,376	1,593	1,887	2,274
Total Revenue	890	1,117	1,314	1,491	1,704	1,860	1,846	2,096	2,419	2,854
Operating Revenue	890	1,117	1,314	1,491	1,704	1,860	1,846	2,096	2,419	2,854
Total Cost of Revenue	152	210	242	315	359	524	471	503	532	580
Operating Cost of Revenue	152	210	242	315	359	524	471	503	532	580
Total Operating Expenses	849	1,711	1,087	1,299	1,445	1,380	1,458	1,432	1,701	1,789
Selling, General & Admin Expense	402	477	554	604	681	738	759	823	892	1,009
Research & Development Expense	635	662	611	696	715	628	629	650	747	747
Amortization Expense	-18	-27	46	49	74	67	70	67	62	43
Other Special Charges / (Income)	-369	0.00	-125	-50	-25	-53	0.00	-108	0.00	-10
Total Other Income / (Expense), net	-44	-28	-21	-19	5.65	-5.56	6.99	-11	2.79	58
Interest Expense	38	39	43	44	23	29	15	16	17	13
Interest & Investment Income	3.68	6.95	14	22	23	17	10	18	58	75
Other Income / (Expense), net	-9.46	4.93	7.97	2.21	6.36	7.14	12	-13	-38	-4.67
Income Tax Expense	17	-201	81	-65	-71	-903	-11	8.02	21	115
Basic Earnings per Share	($1.07)	($3.80)	($0.67)	($0.44)	($0.13)	$4.72	($0.35)	$0.76	$0.89	$2.25
Weighted Average Basic Shares Outstanding	160.03M	165.99M	174.43M	177.06M	179.04M	180.80M	182.85M	185.27M	187.83M	190.03M
Diluted Earnings per Share	($1.07)	($3.81)	($0.67)	($0.44)	($0.13)	$4.50	($0.35)	$0.75	$0.87	$2.21
Weighted Average Diluted Shares Outstanding	160.03M	166.22M	174.43M	177.27M	179.04M	191.68M	182.85M	188.96M	191.60M	196.71M
Weighted Average Basic & Diluted Shares Outstanding	160.60M	165.80M	174.70M	175.50M	359.85M	181.83M	184.03M	186.53M	188.68M	190.78M

This table shows BioMarin Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-6.65	-0.25	51	56	40	20	89	107	106	125
Consolidated Net Income / (Loss)	-6.65	-0.25	51	56	40	20	89	107	106	125
Net Income / (Loss) Continuing Operations	-6.65	-0.25	51	56	40	20	89	107	106	125
Total Pre-Tax Income	-1.90	-18	57	71	42	19	106	132	134	170
Total Operating Income	-2.42	-13	62	66	31	27	88	120	114	161
Total Gross Profit	389	391	461	465	453	508	524	582	557	611
Total Revenue	505	538	596	595	581	646	649	712	746	747
Operating Revenue	505	538	596	595	581	646	649	712	746	747
Total Cost of Revenue	116	147	135	131	128	138	125	130	188	136
Operating Cost of Revenue	116	147	135	131	128	138	125	130	188	136
Total Operating Expenses	391	404	399	399	423	481	435	461	443	450
Selling, General & Admin Expense	217	215	211	206	216	260	226	263	253	267
Research & Development Expense	158	173	172	177	191	206	205	184	185	174
Amortization Expense	17	16	16	16	16	15	14	14	5.01	9.65
Total Other Income / (Expense), net	0.51	-4.47	-5.65	5.24	11	-7.95	17	12	21	8.23
Interest Expense	4.68	3.63	3.70	3.76	3.78	6.10	3.55	3.57	2.97	2.58
Interest & Investment Income	5.00	8.71	12	13	16	18	19	20	18	18
Other Income / (Expense), net	0.19	-9.55	-14	-3.61	-0.82	-20	1.27	-4.53	5.46	-6.87
Income Tax Expense	4.75	-17	5.91	15	1.29	-1.05	17	25	28	45
Basic Earnings per Share	($0.04)	($0.01)	$0.27	$0.30	$0.21	$0.11	$0.47	$0.56	$0.56	$0.66
Weighted Average Basic Shares Outstanding	185.60M	185.27M	186.67M	187.95M	188.22M	187.83M	188.87M	190.11M	190.43M	190.03M
Diluted Earnings per Share	($0.04)	$0.01	$0.27	$0.29	$0.21	$0.10	$0.46	$0.55	$0.55	$0.65
Weighted Average Diluted Shares Outstanding	185.60M	188.96M	194.36M	195.00M	191.17M	191.60M	199.26M	200.51M	197.15M	196.71M
Weighted Average Basic & Diluted Shares Outstanding	185.85M	186.53M	187.70M	188.17M	188.37M	188.68M	189.88M	190.38M	190.58M	190.78M

This table details how cash moves in and out of BioMarin Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-478	11	190	-104	-57	212	-62	137	31	188
Net Cash From Operating Activities	-219	-228	-8.76	20	48	85	305	176	159	573
Net Cash From Continuing Operating Activities	-219	-228	-8.76	20	48	85	305	176	159	573
Net Income / (Loss) Continuing Operations	-172	-630	-117	-77	-24	854	-64	142	168	427
Consolidated Net Income / (Loss)	-172	-630	-117	-77	-24	854	-64	142	168	427
Depreciation Expense	47	97	88	96	105	105	108	102	104	96
Amortization Expense	31	31	35	32	12	17	9.30	7.16	-5.04	-4.99
Non-Cash Adjustments To Reconcile Net Income	-67	720	24	79	133	220	193	72	274	215
Changes in Operating Assets and Liabilities, net	-59	-445	-39	-109	-179	-1,110	58	-147	-382	-160
Net Cash From Investing Activities	-1,180	-484	-305	264	-31	-54	-366	-20	-111	136
Net Cash From Continuing Investing Activities	-1,180	-484	-305	264	-31	-54	-366	-20	-111	136
Purchase of Property, Plant & Equipment	-228	-148	-199	-145	-145	-114	-96	-121	-97	-85
Acquisitions	-538	-2.79	0.00	0.00	-18	-23	-24	-11	-11	-12
Purchase of Investments	-873	-700	-655	-635	-632	-530	-937	-612	-868	-410
Sale and/or Maturity of Investments	425	368	426	994	740	556	691	620	865	633
Other Investing Activities, net	-375	-0.70	-1.75	50	24	58	-0.99	103	0.00	11
Net Cash From Financing Activities	926	727	507	-388	-75	181	-0.05	-19	-19	-526
Net Cash From Continuing Financing Activities	926	727	507	-388	-75	181	-0.05	-19	-19	-526
Repayment of Debt	-2.59	-0.59	-0.03	-375	-5.09	-382	-3.44	-2.61	-2.29	-498
Issuance of Common Equity	951	787	61	67	32	72	49	69	69	49
Other Financing Activities, net	-23	-59	-35	-81	-101	-45	-46	-85	-86	-78
Effect of Exchange Rate Changes	-5.07	-3.93	-3.23	-0.60	0.90	-1.15	-0.06	0.03	1.31	4.83
Cash Interest Paid	9.31	8.64	8.54	12	8.55	12	10	10	10	10
Cash Income Taxes Paid	16	96	24	17	9.73	8.98	18	54	73	57

This table details how cash moves in and out of BioMarin Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	142	-37	-144	114	91	-30	-8.13	225	-297	267
Net Cash From Operating Activities	158	6.79	-74	70	136	27	47	119	221	186
Net Cash From Continuing Operating Activities	158	6.79	-74	70	136	27	47	119	221	186
Net Income / (Loss) Continuing Operations	-6.65	-0.25	51	56	40	20	89	107	106	125
Consolidated Net Income / (Loss)	-6.65	-0.25	51	56	40	20	89	107	106	125
Depreciation Expense	25	25	26	25	26	27	27	26	19	24
Amortization Expense	1.70	0.33	-0.94	-1.53	-1.11	-1.46	-1.51	-1.19	-1.22	-1.07
Non-Cash Adjustments To Reconcile Net Income	50	47	73	52	46	104	38	52	46	79
Changes in Operating Assets and Liabilities, net	88	-65	-223	-61	25	-122	-105	-66	51	-41
Net Cash From Investing Activities	-23	-55	-30	30	-46	-65	-14	90	-16	76
Net Cash From Continuing Investing Activities	-23	-55	-30	30	-46	-65	-14	90	-16	76
Purchase of Property, Plant & Equipment	-29	-36	-24	-22	-22	-29	-26	-21	-18	-20
Acquisitions	-7.17	-0.67	-0.31	-1.15	-1.68	-7.78	-8.00	-0.51	-2.71	-0.77
Purchase of Investments	-153	-154	-220	-224	-283	-141	-122	-74	-157	-58
Sale and/or Maturity of Investments	166	143	215	276	261	113	132	186	161	155
Net Cash From Financing Activities	7.54	11	-41	12	-0.79	11	-43	13	-499	2.86
Net Cash From Continuing Financing Activities	7.54	11	-41	12	-0.79	11	-43	13	-499	2.86
Repayment of Debt	-0.51	-0.97	-1.01	-0.62	-0.61	-0.05	-0.04	-0.02	-498	-0.09
Issuance of Common Equity	14	25	21	29	4.36	15	7.20	29	4.80	7.86
Other Financing Activities, net	-6.32	-14	-61	-16	-4.54	-3.92	-50	-17	-5.91	-4.91
Effect of Exchange Rate Changes	-0.75	0.07	0.23	2.75	1.97	-3.65	1.93	3.30	-2.90	2.50
Cash Interest Paid	1.44	3.71	1.44	3.74	1.47	3.66	1.42	3.71	1.53	3.71
Cash Income Taxes Paid	1.60	41	4.36	24	24	22	2.30	21	13	21

This table presents BioMarin Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	3,729	4,024	4,633	4,427	4,690	5,848	6,005	6,375	6,842	6,989
Total Current Assets	1,090	1,422	2,207	2,056	1,942	2,342	2,274	2,751	2,956	3,232
Cash & Equivalents	397	408	598	494	437	649	587	725	755	943
Short-Term Investments	196	381	798	590	316	416	427	567	319	195
Accounts Receivable	165	215	261	343	377	448	373	461	634	661
Inventories, net	272	355	476	531	680	699	777	894	1,107	1,233
Other Current Assets	60	62	74	98	131	130	110	105	141	202
Plant, Property, & Equipment, net	704	799	897	949	1,011	1,032	1,035	1,073	1,066	1,043
Total Noncurrent Assets	1,936	1,803	1,529	1,422	1,737	2,473	2,695	2,550	2,819	2,713
Long-Term Investments	426	573	386	236	412	285	508	334	611	521
Goodwill	197	197	197	197	197	196	196	196	196	196
Intangible Assets	684	554	518	492	457	417	389	339	295	255
Noncurrent Deferred & Refundable Income Taxes	220	447	399	461	549	1,432	1,450	1,505	1,546	1,489
Other Noncurrent Operating Assets	409	33	30	37	122	142	152	176	172	251
Total Liabilities & Shareholders' Equity	3,729	4,024	4,633	4,427	4,690	5,848	6,005	6,375	6,842	6,989
Total Liabilities	1,329	1,257	1,824	1,459	1,568	1,742	1,739	1,772	1,890	1,331
Total Current Liabilities	445	439	817	523	933	493	546	589	1,177	607
Short-Term Debt	53	69	415	86	362	0.00	48	16	494	0.00
Accounts Payable	393	371	402	437	571	493	498	573	683	607
Total Noncurrent Liabilities	883	818	1,008	936	635	1,249	1,193	1,183	713	724
Long-Term Debt	662	661	814	830	486	1,075	1,079	1,083	593	595
Other Noncurrent Operating Liabilities	77	157	194	106	149	174	114	100	120	129
Total Equity & Noncontrolling Interests	2,401	2,766	2,809	2,968	3,122	4,106	4,266	4,603	4,952	5,658
Total Preferred & Common Equity	2,401	2,766	2,809	2,968	3,122	4,106	4,266	4,603	4,952	5,658
Total Common Equity	2,401	2,766	2,809	2,968	3,122	4,106	4,266	4,603	4,952	5,658
Common Stock	3,415	4,288	4,483	4,670	4,833	4,994	5,192	5,405	5,612	5,802
Retained Earnings	-1,022	-1,521	-1,638	-1,694	-1,721	-862	-931	-789	-622	-195
Accumulated Other Comprehensive Income / (Loss)	21	13	-23	5.27	20	-16	14	-3.87	-29	62
Other Equity Adjustments	-14	-14	-14	-13	-9.96	-9.84	-9.69	-8.86	-9.86	-11

This table presents BioMarin Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	6,264	6,434	6,563	6,758	6,873	7,067	6,851
Total Current Assets	2,683	2,842	2,950	2,955	2,985	3,260	3,057
Cash & Equivalents	762	580	694	785	747	972	675
Short-Term Investments	512	572	477	340	300	252	255
Accounts Receivable	420	598	610	572	637	691	778
Inventories, net	839	919	976	1,032	1,138	1,184	1,179
Other Current Assets	150	173	193	225	163	160	169
Plant, Property, & Equipment, net	1,052	1,068	1,067	1,067	1,060	1,053	1,045
Total Noncurrent Assets	2,530	2,523	2,546	2,736	2,827	2,755	2,749
Long-Term Investments	372	341	386	548	621	557	562
Goodwill	196	196	196	196	196	196	196
Intangible Assets	354	326	310	302	280	266	261
Noncurrent Deferred & Refundable Income Taxes	1,455	1,511	1,509	1,524	1,546	1,545	1,531
Other Noncurrent Operating Assets	152	150	144	165	185	191	199
Total Liabilities & Shareholders' Equity	6,264	6,434	6,563	6,758	6,873	7,067	6,851
Total Liabilities	1,696	1,775	1,780	1,861	1,799	1,781	1,438
Total Current Liabilities	521	598	597	1,163	1,088	1,067	716
Short-Term Debt	28	0.00	0.00	493	494	495	0.00
Accounts Payable	493	598	597	670	594	573	716
Total Noncurrent Liabilities	1,175	1,176	1,183	698	711	713	722
Long-Term Debt	1,082	1,084	1,085	593	594	594	595
Other Noncurrent Operating Liabilities	92	92	98	105	117	119	128
Total Equity & Noncontrolling Interests	4,569	4,659	4,783	4,897	5,074	5,286	5,413
Total Preferred & Common Equity	4,569	4,659	4,783	4,897	5,074	5,286	5,413
Total Common Equity	4,569	4,659	4,783	4,897	5,074	5,286	5,413
Common Stock	5,336	5,418	5,494	5,543	5,619	5,697	5,740
Retained Earnings	-789	-738	-682	-642	-533	-426	-320
Accumulated Other Comprehensive Income / (Loss)	31	-11	-19	6.26	-1.05	27	4.65
Other Equity Adjustments	-9.33	-9.95	-10	-10	-12	-12	-12

This table displays calculated financial ratios and metrics derived from BioMarin Pharmaceutical's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.77%	25.50%	17.62%	13.52%	14.27%	9.18%	-0.76%	13.53%	15.42%	17.97%
EBITDA Growth	-225.97%	-1,484.51%	117.38%	-94.94%	292.83%	271.11%	-45.50%	447.85%	-3.79%	131.26%
EBIT Growth	-28.81%	-564.51%	99.16%	-1,702.66%	22.44%	61.43%	-94.21%	309.25%	0.03%	224.99%
NOPAT Growth	-19.17%	-625.76%	98.17%	-740.30%	18.67%	56.76%	-89.55%	364.32%	8.41%	130.99%
Net Income Growth	-28.24%	-266.83%	81.43%	34.03%	69.11%	3,681.13%	-107.50%	320.91%	18.43%	154.62%
EPS Growth	-16.30%	-256.07%	82.41%	34.33%	70.45%	3,561.54%	-107.78%	314.29%	16.00%	154.02%
Operating Cash Flow Growth	-211.69%	-3.80%	96.16%	330.76%	138.83%	76.88%	256.75%	-42.24%	-9.46%	259.69%
Free Cash Flow Firm Growth	-312.03%	42.70%	77.95%	-199.98%	21.41%	-239.65%	90.66%	46.21%	-110.44%	226.17%
Invested Capital Growth	85.38%	1.70%	5.70%	13.71%	9.38%	36.57%	1.07%	5.31%	6.79%	5.53%
Revenue Q/Q Growth	-0.16%	6.91%	4.64%	-0.34%	6.32%	-0.12%	-0.12%	4.37%	4.70%	3.67%
EBITDA Q/Q Growth	77.54%	-36.28%	390.33%	-94.98%	330.09%	-30.75%	-28.66%	17.28%	14.12%	33.82%
EBIT Q/Q Growth	57.12%	-30.40%	95.62%	-560.24%	25.59%	-3,343.79%	-34.84%	39.58%	25.54%	44.27%
NOPAT Q/Q Growth	59.12%	-31.17%	90.95%	-351.99%	22.39%	-3,896.32%	-21.13%	68.77%	27.17%	43.73%
Net Income Q/Q Growth	44.62%	-33.84%	25.15%	38.21%	43.92%	0.24%	-690.82%	68.70%	14.03%	32.45%
EPS Q/Q Growth	46.77%	-34.15%	22.99%	38.89%	48.00%	2.51%	-305.88%	74.42%	11.54%	33.13%
Operating Cash Flow Q/Q Growth	-23.62%	22.37%	62.86%	238.87%	19.78%	-45.31%	8.77%	-2.44%	14.94%	38.13%
Free Cash Flow Firm Q/Q Growth	1.70%	-24.82%	73.63%	-85.22%	0.61%	-10.36%	39.24%	44.82%	23.70%	139.28%
Invested Capital Q/Q Growth	9.15%	8.17%	-4.40%	0.43%	1.06%	2.65%	0.65%	1.09%	1.03%	1.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	82.92%	81.23%	81.59%	78.86%	78.91%	71.82%	74.52%	76.00%	78.01%	79.67%
EBITDA Margin	-4.75%	-60.02%	8.87%	0.40%	1.36%	4.62%	2.54%	12.24%	10.21%	20.01%
Operating Margin	-12.44%	-71.94%	-1.12%	-8.28%	-5.90%	-2.33%	-4.46%	7.68%	7.68%	16.97%
EBIT Margin	-13.50%	-71.50%	-0.51%	-8.14%	-5.52%	-1.95%	-3.82%	7.04%	6.10%	16.80%
Profit (Net Income) Margin	-19.31%	-56.43%	-8.91%	-5.18%	-1.40%	45.90%	-3.47%	6.75%	6.93%	14.96%
Tax Burden Percent	111.04%	75.83%	326.25%	54.11%	25.15%	-1,743.02%	85.04%	94.64%	88.91%	78.79%
Interest Burden Percent	128.76%	104.08%	533.06%	117.63%	100.76%	134.99%	106.89%	101.40%	127.79%	112.97%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.36%	11.09%	21.21%
Return on Invested Capital (ROIC)	-4.80%	-26.58%	-0.47%	-3.59%	-2.62%	-0.92%	-1.50%	3.83%	3.92%	8.53%
ROIC Less NNEP Spread (ROIC-NNEP)	22.17%	-12.09%	17.53%	-5.52%	-15.50%	-299.02%	0.43%	6.18%	3.48%	3.07%
Return on Net Nonoperating Assets (RNNOA)	-3.95%	2.19%	-3.73%	0.92%	1.84%	24.55%	-0.03%	-0.64%	-0.41%	-0.48%
Return on Equity (ROE)	-8.75%	-24.39%	-4.20%	-2.67%	-0.78%	23.63%	-1.53%	3.19%	3.51%	8.05%
Cash Return on Invested Capital (CROIC)	-64.63%	-28.27%	-6.01%	-16.42%	-11.58%	-31.83%	-2.56%	-1.34%	-2.65%	3.15%
Operating Return on Assets (OROA)	-3.87%	-20.60%	-0.16%	-2.68%	-2.06%	-0.69%	-1.19%	2.38%	2.23%	6.93%
Return on Assets (ROA)	-5.54%	-16.26%	-2.70%	-1.70%	-0.52%	16.21%	-1.08%	2.29%	2.54%	6.17%
Return on Common Equity (ROCE)	-8.75%	-24.39%	-4.20%	-2.67%	-0.78%	23.63%	-1.53%	3.19%	3.51%	8.05%
Return on Equity Simple (ROE_SIMPLE)	-7.16%	-22.78%	-4.17%	-2.60%	-0.76%	20.80%	-1.50%	3.08%	3.39%	7.54%
Net Operating Profit after Tax (NOPAT)	-77	-562	-10	-86	-70	-30	-58	152	165	382
NOPAT Margin	-8.71%	-50.36%	-0.78%	-5.80%	-4.13%	-1.63%	-3.12%	7.27%	6.83%	13.37%
Net Nonoperating Expense Percent (NNEP)	-26.97%	-14.49%	-18.00%	1.93%	12.88%	298.10%	-1.92%	-2.34%	0.44%	5.46%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	2.67%	2.74%	6.10%
Cost of Revenue to Revenue	17.08%	18.77%	18.41%	21.14%	21.09%	28.18%	25.48%	24.00%	21.99%	20.33%
SG&A Expenses to Revenue	45.20%	42.67%	42.20%	40.53%	39.96%	39.65%	41.13%	39.28%	36.89%	35.36%
R&D to Revenue	71.33%	59.27%	46.49%	46.70%	41.96%	33.76%	34.06%	30.99%	30.87%	26.18%
Operating Expenses to Revenue	95.36%	153.17%	82.71%	87.14%	84.80%	74.16%	78.98%	68.32%	70.33%	62.70%
Earnings before Interest and Taxes (EBIT)	-120	-799	-6.73	-121	-94	-36	-70	148	148	480
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-42	-670	117	5.90	23	86	47	257	247	571
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.04	5.15	5.58	5.11	4.86	3.88	3.80	4.18	3.67	2.21
Price to Tangible Book Value (P/TBV)	11.12	7.07	7.48	6.65	6.15	4.56	4.41	4.73	4.07	2.41
Price to Revenue (P/Rev)	18.98	12.76	11.92	10.17	8.91	8.56	8.79	9.18	7.51	4.39
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	18.64	0.00	135.87	108.34	29.35
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	5.37%	0.00%	0.74%	0.92%	3.41%
Enterprise Value to Invested Capital (EV/IC)	7.91	6.38	6.70	5.76	5.30	4.08	4.09	4.59	4.03	2.50
Enterprise Value to Revenue (EV/Rev)	18.64	12.19	11.50	9.90	8.73	8.41	8.57	8.93	7.26	4.02
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	129.66	2,503.08	642.01	181.99	337.84	72.89	71.14	20.08
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	126.82	119.03	23.90
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	122.79	106.34	30.05
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	730.31	308.10	183.24	51.97	106.35	110.29	20.01
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	81.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.30	0.26	0.44	0.31	0.27	0.26	0.26	0.24	0.22	0.11
Long-Term Debt to Equity	0.28	0.24	0.29	0.28	0.16	0.26	0.25	0.24	0.12	0.11
Financial Leverage	-0.18	-0.18	-0.21	-0.17	-0.12	-0.08	-0.08	-0.10	-0.12	-0.16
Leverage Ratio	1.58	1.50	1.55	1.57	1.50	1.46	1.42	1.40	1.38	1.30
Compound Leverage Factor	2.03	1.56	8.28	1.84	1.51	1.97	1.51	1.42	1.77	1.47
Debt to Total Capital	22.95%	20.87%	30.42%	23.59%	21.36%	20.75%	20.90%	19.27%	18.00%	9.52%
Short-Term Debt to Total Capital	1.70%	1.97%	10.27%	2.21%	9.11%	0.00%	0.89%	0.28%	8.18%	0.00%
Long-Term Debt to Total Capital	21.25%	18.90%	20.15%	21.38%	12.25%	20.75%	20.01%	18.99%	9.82%	9.52%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	77.05%	79.13%	69.58%	76.41%	78.64%	79.25%	79.10%	80.73%	82.00%	90.48%
Debt to EBITDA	-16.91	-1.09	10.54	155.42	36.62	12.51	24.06	4.28	4.40	1.04
Net Debt to EBITDA	7.16	0.94	-4.75	-68.49	-13.72	-3.21	-8.42	-2.05	-2.42	-1.86
Long-Term Debt to EBITDA	-15.65	-0.99	6.98	140.84	20.99	12.51	23.04	4.22	2.40	1.04
Debt to NOPAT	-9.23	-1.30	-119.35	-10.60	-12.06	-35.36	-19.56	7.21	6.58	1.56
Net Debt to NOPAT	3.91	1.13	53.80	4.67	4.52	9.07	6.84	-3.46	-3.62	-2.79
Long-Term Debt to NOPAT	-8.55	-1.17	-79.06	-9.60	-6.91	-35.36	-18.72	7.11	3.59	1.56
Altman Z-Score	7.59	6.19	5.29	6.36	5.85	5.95	5.99	7.15	6.38	6.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.45	3.24	2.70	3.93	2.08	4.76	4.16	4.67	2.51	5.33
Quick Ratio	1.70	2.29	2.03	2.73	1.21	3.07	2.54	2.98	1.45	2.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1,044	-598	-132	-396	-311	-1,056	-99	-53	-112	141
Operating Cash Flow to CapEx	-96.42%	-153.55%	-4.40%	13.97%	33.28%	74.68%	318.63%	145.42%	164.71%	670.59%
Free Cash Flow to Firm to Interest Expense	-27.29	-15.14	-3.09	-9.06	-13.25	-36.03	-6.43	-3.32	-6.44	11.12
Operating Cash Flow to Interest Expense	-5.74	-5.77	-0.21	0.46	2.06	2.91	19.86	11.01	9.19	45.23
Operating Cash Flow Less CapEx to Interest Expense	-11.69	-9.52	-4.87	-2.85	-4.12	-0.99	13.62	3.44	3.61	38.48
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.29	0.29	0.30	0.33	0.37	0.35	0.31	0.34	0.37	0.41
Accounts Receivable Turnover	5.75	5.87	5.51	4.94	4.73	4.51	4.49	5.02	4.42	4.41
Inventory Turnover	0.65	0.67	0.58	0.63	0.59	0.76	0.64	0.60	0.53	0.50
Fixed Asset Turnover	1.45	1.49	1.55	1.62	1.74	1.82	1.79	1.99	2.26	2.71
Accounts Payable Turnover	0.49	0.55	0.63	0.75	0.71	0.99	0.95	0.94	0.85	0.90
Days Sales Outstanding (DSO)	63.46	62.13	66.22	73.92	77.11	81.00	81.23	72.68	82.61	82.76
Days Inventory Outstanding (DIO)	565.64	545.71	627.16	582.73	614.90	479.97	572.20	606.16	686.44	735.94
Days Payable Outstanding (DPO)	749.60	664.30	583.03	485.80	511.71	370.09	384.31	388.65	430.85	405.78
Cash Conversion Cycle (CCC)	-120.50	-56.45	110.36	170.84	180.30	190.88	269.12	290.19	338.20	412.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,098	2,133	2,255	2,564	2,805	3,830	3,871	4,077	4,354	4,594
Invested Capital Turnover	0.55	0.53	0.60	0.62	0.63	0.56	0.48	0.53	0.57	0.64
Increase / (Decrease) in Invested Capital	966	36	122	309	241	1,026	41	205	277	241
Enterprise Value (EV)	16,590	13,615	15,107	14,758	14,870	15,643	15,826	18,707	17,564	11,463
Market Capitalization	16,893	14,247	15,660	15,162	15,187	15,918	16,220	19,234	18,162	12,527
Book Value per Share	$14.89	$16.08	$15.99	$16.67	$17.38	$22.62	$23.23	$24.77	$26.29	$29.69
Tangible Book Value per Share	$9.43	$11.72	$11.92	$12.80	$13.74	$19.24	$20.05	$21.89	$23.68	$27.32
Total Capital	3,116	3,496	4,037	3,884	3,971	5,181	5,393	5,702	6,039	6,253
Total Debt	715	730	1,228	916	848	1,075	1,127	1,099	1,087	595
Total Long-Term Debt	662	661	814	830	486	1,075	1,079	1,083	593	595
Net Debt	-303	-633	-554	-404	-318	-276	-394	-526	-598	-1,064
Capital Expenditures (CapEx)	228	148	199	145	145	114	96	121	97	85
Debt-free, Cash-free Net Working Capital (DFCFNWC)	105	262	409	535	618	784	762	887	1,199	1,488
Debt-free Net Working Capital (DFNWC)	697	1,051	1,805	1,619	1,372	1,850	1,776	2,178	2,273	2,625
Net Working Capital (NWC)	644	982	1,391	1,533	1,010	1,850	1,728	2,163	1,779	2,625
Net Nonoperating Expense (NNE)	94	68	107	-9.26	-46	-884	6.44	11	-2.48	-45
Net Nonoperating Obligations (NNO)	-303	-633	-554	-404	-318	-276	-394	-526	-598	-1,064
Total Depreciation and Amortization (D&A)	78	128	123	127	117	122	117	109	99	91
Debt-free, Cash-free Net Working Capital to Revenue	11.74%	23.42%	31.15%	35.85%	36.25%	42.16%	41.29%	42.32%	49.57%	52.13%
Debt-free Net Working Capital to Revenue	78.34%	94.13%	137.42%	108.56%	80.49%	99.42%	96.20%	103.93%	93.95%	91.99%
Net Working Capital to Revenue	72.39%	87.97%	105.86%	102.80%	59.25%	99.42%	93.59%	103.17%	73.54%	91.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.07)	($3.80)	($0.67)	($0.44)	($0.13)	$4.75	($0.35)	$0.76	$0.89	$2.25
Adjusted Weighted Average Basic Shares Outstanding	161.59M	165.99M	174.43M	177.06M	179.04M	180.80M	182.85M	185.27M	187.83M	190.03M
Adjusted Diluted Earnings per Share	($1.07)	($3.81)	($0.67)	($0.44)	($0.13)	$4.53	($0.35)	$0.75	$0.87	$2.21
Adjusted Weighted Average Diluted Shares Outstanding	161.59M	166.22M	174.43M	177.27M	179.04M	191.68M	182.85M	188.96M	191.60M	196.71M
Adjusted Basic & Diluted Earnings per Share	($1.07)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	160.03M	172.87M	176.07M	178.37M	359.85M	181.83M	184.03M	186.53M	188.68M	190.78M
Normalized Net Operating Profit after Tax (NOPAT)	-197	-143	-98	-121	-88	-67	-58	50	165	374
Normalized NOPAT Margin	-22.14%	-12.81%	-7.44%	-8.15%	-5.15%	-3.62%	-3.12%	2.39%	6.83%	13.09%
Pre Tax Income Margin	-17.39%	-74.41%	-2.73%	-9.57%	-5.56%	-2.63%	-4.08%	7.14%	7.79%	18.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3.14	-20.22	-0.16	-2.78	-4.01	-1.24	-4.60	9.24	8.51	37.86
NOPAT to Interest Expense	-2.03	-14.24	-0.24	-1.98	-3.00	-1.04	-3.76	9.54	9.53	30.12
EBIT Less CapEx to Interest Expense	-9.09	-23.97	-4.82	-6.09	-10.19	-5.14	-10.83	1.66	2.93	31.12
NOPAT Less CapEx to Interest Expense	-7.98	-17.99	-4.91	-5.29	-9.18	-4.94	-9.99	1.97	3.95	23.38
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	5.85%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from BioMarin Pharmaceutical's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	23.63%	19.50%	14.84%	11.52%	15.04%	20.22%	8.79%	19.61%	28.28%	15.65%
EBITDA Growth	263.53%	106.30%	-55.48%	34.28%	123.62%	1,362.96%	56.18%	64.50%	152.63%	440.12%
EBIT Growth	94.96%	64.88%	-64.37%	71.12%	1,435.79%	132.60%	84.94%	87.12%	301.76%	1,993.70%
NOPAT Growth	95.46%	80.13%	-54.77%	66.97%	1,848.29%	413.90%	32.91%	88.28%	203.82%	313.38%
Net Income Growth	81.77%	99.57%	-57.90%	102.57%	707.01%	8,282.73%	74.35%	91.25%	162.72%	513.22%
EPS Growth	80.00%	103.23%	-57.14%	93.33%	625.00%	900.00%	70.37%	89.66%	161.90%	550.00%
Operating Cash Flow Growth	63.12%	-39.30%	-62.73%	24.61%	-14.32%	305.00%	163.53%	69.51%	63.28%	575.42%
Free Cash Flow Firm Growth	-23.74%	-146.25%	-450.42%	10.57%	-31.11%	-15.62%	4.54%	-11.71%	52.69%	50.93%
Invested Capital Growth	4.85%	5.31%	5.83%	5.31%	6.85%	6.79%	5.75%	6.56%	4.79%	5.53%
Revenue Q/Q Growth	-5.33%	6.37%	10.95%	-0.19%	-2.34%	11.16%	0.41%	9.74%	4.73%	0.21%
EBITDA Q/Q Growth	-62.02%	-90.77%	3,201.96%	16.00%	-36.76%	-39.61%	252.50%	22.18%	-2.88%	29.12%
EBIT Q/Q Growth	-106.14%	-918.08%	314.28%	27.69%	-52.05%	-75.15%	1,115.68%	29.19%	2.96%	29.47%
NOPAT Q/Q Growth	-105.44%	-441.50%	426.01%	-7.19%	-43.00%	-2.78%	1,478.33%	31.47%	-8.02%	32.28%
Net Income Q/Q Growth	-124.05%	96.26%	20,522.49%	10.20%	-27.95%	-49.54%	335.15%	20.88%	-1.02%	17.78%
EPS Q/Q Growth	-126.67%	125.00%	2,600.00%	7.41%	-27.59%	-52.38%	360.00%	19.57%	0.00%	18.18%
Operating Cash Flow Q/Q Growth	181.58%	-95.71%	-1,189.48%	194.77%	93.61%	-79.74%	70.91%	152.84%	86.49%	-16.19%
Free Cash Flow Firm Q/Q Growth	-1.57%	-14.06%	19.98%	7.00%	-48.92%	-0.57%	37.53%	-8.84%	36.93%	-4.31%
Invested Capital Q/Q Growth	-1.48%	1.09%	4.26%	1.43%	-0.05%	1.03%	3.24%	2.21%	-1.70%	1.74%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	76.99%	72.72%	77.29%	78.06%	77.97%	78.66%	80.71%	81.68%	74.73%	81.78%
EBITDA Margin	4.80%	0.42%	12.41%	14.42%	9.34%	5.07%	17.81%	19.83%	18.39%	23.70%
Operating Margin	-0.48%	-2.43%	10.46%	11.01%	5.25%	4.22%	13.63%	16.92%	15.27%	21.60%
EBIT Margin	-0.44%	-4.21%	8.13%	10.41%	5.11%	1.14%	13.83%	16.28%	16.01%	20.68%
Profit (Net Income) Margin	-1.32%	-0.05%	8.53%	9.41%	6.95%	3.15%	13.66%	15.05%	14.22%	16.72%
Tax Burden Percent	349.37%	1.42%	89.60%	79.14%	96.90%	105.42%	84.00%	81.11%	78.90%	73.65%
Interest Burden Percent	85.61%	77.55%	116.98%	114.30%	140.26%	261.85%	117.63%	113.98%	112.64%	109.77%
Effective Tax Rate	0.00%	0.00%	10.40%	20.86%	3.10%	-5.42%	16.00%	18.89%	21.10%	26.35%
Return on Invested Capital (ROIC)	-0.17%	-0.90%	4.93%	4.64%	2.82%	2.55%	6.47%	7.98%	7.52%	10.15%
ROIC Less NNEP Spread (ROIC-NNEP)	0.87%	-2.83%	6.22%	3.70%	0.90%	4.05%	3.57%	6.35%	5.34%	9.42%
Return on Net Nonoperating Assets (RNNOA)	-0.09%	0.29%	-0.54%	-0.35%	-0.11%	-0.48%	-0.36%	-0.73%	-0.77%	-1.48%
Return on Equity (ROE)	-0.26%	-0.60%	4.39%	4.28%	2.71%	2.08%	6.11%	7.24%	6.75%	8.67%
Cash Return on Invested Capital (CROIC)	-2.44%	-1.34%	-3.87%	-2.95%	-3.51%	-2.65%	-1.94%	-1.74%	1.33%	3.15%
Operating Return on Assets (OROA)	-0.14%	-1.43%	2.83%	3.66%	1.81%	0.42%	5.14%	6.18%	6.47%	8.53%
Return on Assets (ROA)	-0.43%	-0.02%	2.97%	3.31%	2.46%	1.15%	5.08%	5.72%	5.75%	6.90%
Return on Common Equity (ROCE)	-0.26%	-0.60%	4.39%	4.28%	2.71%	2.08%	6.11%	7.24%	6.75%	8.67%
Return on Equity Simple (ROE_SIMPLE)	1.84%	0.00%	1.54%	2.09%	3.00%	0.00%	4.05%	4.85%	5.95%	0.00%
Net Operating Profit after Tax (NOPAT)	-1.69	-9.16	56	52	30	29	74	98	90	119
NOPAT Margin	-0.33%	-1.70%	9.37%	8.72%	5.09%	4.45%	11.45%	13.72%	12.05%	15.91%
Net Nonoperating Expense Percent (NNEP)	-1.04%	1.94%	-1.29%	0.94%	1.92%	-1.49%	2.91%	1.63%	2.18%	0.73%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.16%	-	-	-	0.48%	-	-	-	1.90%
Cost of Revenue to Revenue	23.01%	27.28%	22.71%	21.94%	22.03%	21.34%	19.29%	18.32%	25.27%	18.22%
SG&A Expenses to Revenue	42.90%	39.99%	35.38%	34.62%	37.12%	40.16%	34.82%	36.94%	33.99%	35.68%
R&D to Revenue	31.23%	32.14%	28.81%	29.80%	32.91%	31.92%	31.59%	25.81%	24.79%	23.22%
Operating Expenses to Revenue	77.47%	75.15%	66.82%	67.04%	72.72%	74.43%	67.07%	64.76%	59.46%	60.18%
Earnings before Interest and Taxes (EBIT)	-2.22	-23	49	62	30	7.38	90	116	119	155
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	24	2.24	74	86	54	33	116	141	137	177
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.44	4.18	3.89	3.40	3.40	3.67	3.24	2.96	2.47	2.21
Price to Tangible Book Value (P/TBV)	3.91	4.73	4.38	3.80	3.79	4.07	3.58	3.24	2.70	2.41
Price to Revenue (P/Rev)	7.83	9.18	8.35	7.28	7.21	7.51	6.66	6.04	4.86	4.39
Price to Earnings (P/E)	187.37	135.87	253.27	162.71	113.25	108.34	80.08	60.93	41.52	29.35
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.53%	0.74%	0.39%	0.61%	0.88%	0.92%	1.25%	1.64%	2.41%	3.41%
Enterprise Value to Invested Capital (EV/IC)	3.77	4.59	4.17	3.66	3.73	4.03	3.53	3.25	2.76	2.50
Enterprise Value to Revenue (EV/Rev)	7.56	8.93	8.16	7.07	6.95	7.26	6.42	5.77	4.54	4.02
Enterprise Value to EBITDA (EV/EBITDA)	69.40	72.89	107.82	84.78	74.24	71.14	55.02	43.45	29.26	20.08
Enterprise Value to EBIT (EV/EBIT)	143.71	126.82	296.20	184.55	136.65	119.03	84.09	61.55	37.56	23.90
Enterprise Value to NOPAT (EV/NOPAT)	168.23	122.79	239.30	169.02	123.67	106.34	99.58	72.75	47.03	30.05
Enterprise Value to Operating Cash Flow (EV/OCF)	84.23	106.35	120.28	97.98	115.92	110.29	56.66	45.43	30.10	20.01
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	212.00	81.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.24	0.24	0.23	0.23	0.22	0.22	0.21	0.21	0.11	0.11
Long-Term Debt to Equity	0.24	0.24	0.23	0.23	0.12	0.12	0.12	0.11	0.11	0.11
Financial Leverage	-0.11	-0.10	-0.09	-0.10	-0.12	-0.12	-0.10	-0.12	-0.14	-0.16
Leverage Ratio	1.39	1.40	1.38	1.37	1.38	1.38	1.37	1.35	1.32	1.30
Compound Leverage Factor	1.19	1.08	1.62	1.56	1.93	3.62	1.61	1.54	1.49	1.43
Debt to Total Capital	19.55%	19.27%	18.88%	18.49%	18.15%	18.00%	17.66%	17.08%	9.90%	9.52%
Short-Term Debt to Total Capital	0.50%	0.28%	0.00%	0.00%	8.25%	8.18%	8.02%	7.76%	0.00%	0.00%
Long-Term Debt to Total Capital	19.05%	18.99%	18.88%	18.49%	9.90%	9.82%	9.63%	9.32%	9.90%	9.52%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	80.45%	80.73%	81.12%	81.51%	81.85%	82.00%	82.34%	82.92%	90.10%	90.48%
Debt to EBITDA	5.07	4.28	6.59	5.82	5.02	4.40	3.77	3.17	1.39	1.04
Net Debt to EBITDA	-2.45	-2.05	-2.49	-2.53	-2.72	-2.42	-2.01	-2.01	-2.10	-1.86
Long-Term Debt to EBITDA	4.94	4.22	6.59	5.82	2.74	2.40	2.06	1.73	1.39	1.04
Debt to NOPAT	12.30	7.21	14.63	11.61	8.36	6.58	6.83	5.30	2.24	1.56
Net Debt to NOPAT	-5.93	-3.46	-5.52	-5.05	-4.53	-3.62	-3.63	-3.37	-3.38	-2.79
Long-Term Debt to NOPAT	11.99	7.11	14.63	11.61	4.56	3.59	3.72	2.89	2.24	1.56
Altman Z-Score	6.12	7.06	6.75	6.14	5.91	6.31	6.11	5.98	6.39	6.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.15	4.67	4.75	4.94	2.54	2.51	2.74	3.05	4.27	5.33
Quick Ratio	3.25	2.98	2.93	2.98	1.46	1.45	1.55	1.79	2.39	2.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-188	-215	-178	-166	-247	-248	-170	-185	-117	-122
Operating Cash Flow to CapEx	540.34%	19.01%	-302.31%	324.62%	624.09%	95.04%	179.94%	556.86%	1,199.59%	950.47%
Free Cash Flow to Firm to Interest Expense	-40.21	-59.18	-48.10	-44.11	-65.28	-40.68	-47.93	-51.77	-39.32	-47.24
Operating Cash Flow to Interest Expense	33.84	1.87	-19.97	18.66	35.89	4.51	13.24	33.23	74.62	72.03
Operating Cash Flow Less CapEx to Interest Expense	27.57	-7.97	-26.57	12.91	30.14	-0.24	5.88	27.26	68.40	64.45
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.34	0.35	0.35	0.35	0.37	0.37	0.38	0.40	0.41
Accounts Receivable Turnover	5.06	5.02	4.23	4.15	4.66	4.42	4.00	3.98	4.08	4.41
Inventory Turnover	0.60	0.60	0.59	0.57	0.56	0.53	0.49	0.47	0.51	0.50
Fixed Asset Turnover	1.93	1.99	2.06	2.11	2.18	2.26	2.32	2.44	2.61	2.71
Accounts Payable Turnover	0.99	0.94	0.98	0.99	0.90	0.85	0.85	0.86	0.82	0.90
Days Sales Outstanding (DSO)	72.20	72.68	86.34	87.94	78.36	82.61	91.19	91.76	89.50	82.76
Days Inventory Outstanding (DIO)	609.01	606.16	619.73	636.61	655.07	686.44	743.98	781.22	714.56	735.94
Days Payable Outstanding (DPO)	367.75	388.65	372.38	369.54	406.89	430.85	431.06	423.23	447.67	405.78
Cash Conversion Cycle (CCC)	313.47	290.19	333.69	355.01	326.54	338.20	404.11	449.75	356.40	412.92
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	4,033	4,077	4,250	4,311	4,309	4,354	4,495	4,594	4,516	4,594
Invested Capital Turnover	0.51	0.53	0.53	0.53	0.55	0.57	0.57	0.58	0.62	0.64
Increase / (Decrease) in Invested Capital	186	205	234	218	276	277	244	283	207	241
Enterprise Value (EV)	15,187	18,707	17,729	15,798	16,062	17,564	15,873	14,940	12,484	11,463
Market Capitalization	15,723	19,234	18,138	16,270	16,650	18,162	16,452	15,633	13,382	12,527
Book Value per Share	$24.63	$24.77	$24.98	$25.48	$26.02	$26.29	$26.86	$27.84	$28.43	$29.69
Tangible Book Value per Share	$21.67	$21.89	$22.18	$22.78	$23.37	$23.68	$24.35	$25.41	$26.03	$27.32
Total Capital	5,679	5,702	5,743	5,868	5,983	6,039	6,162	6,375	6,008	6,253
Total Debt	1,110	1,099	1,084	1,085	1,086	1,087	1,088	1,089	595	595
Total Long-Term Debt	1,082	1,083	1,084	1,085	593	593	594	594	595	595
Net Debt	-536	-526	-409	-472	-588	-598	-579	-692	-898	-1,064
Capital Expenditures (CapEx)	29	36	24	22	22	29	26	21	18	20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	916	887	1,092	1,182	1,160	1,199	1,345	1,463	1,410	1,488
Debt-free Net Working Capital (DFNWC)	2,190	2,178	2,244	2,353	2,285	2,273	2,391	2,687	2,341	2,625
Net Working Capital (NWC)	2,162	2,163	2,244	2,353	1,792	1,779	1,897	2,192	2,341	2,625
Net Nonoperating Expense (NNE)	4.96	-8.91	5.06	-4.15	-11	8.38	-14	-9.48	-16	-6.06
Net Nonoperating Obligations (NNO)	-536	-526	-409	-472	-588	-598	-579	-692	-898	-1,064
Total Depreciation and Amortization (D&A)	27	25	25	24	25	25	26	25	18	23
Debt-free, Cash-free Net Working Capital to Revenue	45.62%	42.32%	50.24%	52.89%	50.19%	49.57%	54.41%	56.51%	51.24%	52.13%
Debt-free Net Working Capital to Revenue	109.05%	103.93%	103.26%	105.29%	98.91%	93.95%	96.76%	103.81%	85.04%	91.99%
Net Working Capital to Revenue	107.64%	103.17%	103.26%	105.29%	77.56%	73.54%	76.76%	84.70%	85.04%	91.99%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.04)	($0.01)	$0.27	$0.30	$0.21	$0.11	$0.47	$0.56	$0.56	$0.66
Adjusted Weighted Average Basic Shares Outstanding	185.60M	185.27M	186.67M	187.95M	188.22M	187.83M	188.87M	190.11M	190.43M	190.03M
Adjusted Diluted Earnings per Share	($0.04)	$0.01	$0.27	$0.29	$0.21	$0.10	$0.46	$0.55	$0.55	$0.65
Adjusted Weighted Average Diluted Shares Outstanding	185.60M	188.96M	194.36M	195.00M	191.17M	191.60M	199.26M	200.51M	197.15M	196.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	185.85M	186.53M	187.70M	188.17M	188.37M	188.68M	189.88M	190.38M	190.58M	190.78M
Normalized Net Operating Profit after Tax (NOPAT)	-1.69	-9.16	56	52	30	19	66	98	90	119
Normalized NOPAT Margin	-0.33%	-1.70%	9.37%	8.72%	5.09%	2.96%	10.16%	13.72%	12.05%	15.91%
Pre Tax Income Margin	-0.38%	-3.27%	9.52%	11.90%	7.17%	2.99%	16.27%	18.56%	18.03%	22.70%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.48	-6.24	13.10	16.50	7.86	1.21	25.30	32.44	40.21	59.97
NOPAT to Interest Expense	-0.36	-2.53	15.10	13.82	7.83	4.72	20.95	27.34	30.28	46.13
EBIT Less CapEx to Interest Expense	-6.74	-16.09	6.50	10.75	2.11	-3.53	17.94	26.47	33.99	52.39
NOPAT Less CapEx to Interest Expense	-6.62	-12.37	8.49	8.07	2.08	-0.03	13.59	21.37	24.06	38.55
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About BioMarin Pharmaceutical's Financials

When does BioMarin Pharmaceutical's financial year end?

According to the most recent income statement we have on file, BioMarin Pharmaceutical's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has BioMarin Pharmaceutical's net income changed over the last 9 years?

BioMarin Pharmaceutical's net income appears to be on an upward trend, with a most recent value of $426.86 million in 2024, falling from -$171.80 million in 2015. The previous period was $167.65 million in 2023.

What is BioMarin Pharmaceutical's operating income?

BioMarin Pharmaceutical's total operating income in 2024 was $484.21 million, based on the following breakdown:

Total Gross Profit: $2.27 billion
Total Operating Expenses: $1.79 billion

How has BioMarin Pharmaceutical revenue changed over the last 9 years?

Over the last 9 years, BioMarin Pharmaceutical's total revenue changed from $889.90 million in 2015 to $2.85 billion in 2024, a change of 220.7%.

How much debt does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical's total liabilities were at $1.33 billion at the end of 2024, a 29.6% decrease from 2023, and a 0.2% increase since 2015.

How much cash does BioMarin Pharmaceutical have?

In the past 9 years, BioMarin Pharmaceutical's cash and equivalents has ranged from $397.04 million in 2015 to $942.84 million in 2024, and is currently $942.84 million as of their latest financial filing in 2024.

How has BioMarin Pharmaceutical's book value per share changed over the last 9 years?

Over the last 9 years, BioMarin Pharmaceutical's book value per share changed from 14.89 in 2015 to 29.69 in 2024, a change of 99.4%.

Related Companies

This page (NASDAQ:BMRN) was last updated on 4/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioMarin Pharmaceutical (BMRN) Financials

Frequently Asked Questions About BioMarin Pharmaceutical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioMarin Pharmaceutical (BMRN) Financials

Annual Income Statements for BioMarin Pharmaceutical

Quarterly Income Statements for BioMarin Pharmaceutical

Annual Cash Flow Statements for BioMarin Pharmaceutical

Quarterly Cash Flow Statements for BioMarin Pharmaceutical

Annual Balance Sheets for BioMarin Pharmaceutical

Quarterly Balance Sheets for BioMarin Pharmaceutical

Annual Metrics and Ratios for BioMarin Pharmaceutical

Quarterly Metrics and Ratios for BioMarin Pharmaceutical

Frequently Asked Questions About BioMarin Pharmaceutical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools